Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 3/20 | 0.61 |
| ▸ | BRD4 | O60885 | 12/20 | 0.56 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.51 |
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | PAK4 | O96013 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | FYN | P06241 | 1/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
| ▸ | IGF1R | P08069 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12694698 | 0.88 | BRD4 (0.53) | BRD4ALKJAK2JAK3EGFR | |
| SCHEMBL12854649 | 0.86 | CTSC (0.58) | CTSCBRD4ALKJAK2JAK3 | |
| SCHEMBL3122460 | 0.83 | CTSC (0.55) | CTSCBRD4ALKJAK2JAK3 | |
| SCHEMBL3108564 | 0.83 | CTSC (0.57) | CTSCBRD4ALKJAK2JAK3 | |
| SCHEMBL3109342 | 0.82 | CTSC (0.56) | CTSCBRD4ALKJAK2JAK3 | |
| SCHEMBL12694807 | 0.82 | BRD4 (0.63) | CTSCBRD4ALKJAK2JAK3 | |
| Formic Acid SCHEMBL14482459 | 0.80 | CTSC (0.52) | CTSCBRD4ALKJAK2JAK3 | |
| Formic Acid SCHEMBL14482025 | 0.80 | CTSC (0.54) | CTSCBRD4ALKJAK2JAK3 | |
| SCHEMBL13268024 | 0.80 | CTSC (0.59) | CTSCBRD4ALKJAK2JAK3 | |
| SCHEMBL12694730 | 0.79 | CTSC (0.59) | CTSCBRD4ALKJAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518937-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20130012501-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2013-01-10 | — | — | US | disclosed |
| US-8278299-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012501-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | PLK1, TK1, DTYMK | CTSC 2302/4885BRD4 758/4885ALK 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.